197 related articles for article (PubMed ID: 29477057)
1. Maintenance proton pump inhibition therapy and risk of oesophageal cancer.
Brusselaers N; Engstrand L; Lagergren J
Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
3. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Brusselaers N; Lagergren J; Engstrand L
Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
[TBL] [Abstract][Full Text] [Related]
4. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
Holmberg D; Mattsson F; Xie S; Ness-Jensen E; El-Serag H; Lagergren J
J Gastroenterol; 2022 Dec; 57(12):942-951. PubMed ID: 36258093
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
Chandanos E; Lindblad M; Jia C; Rubio CA; Ye W; Lagergren J
Br J Cancer; 2006 Jul; 95(1):118-22. PubMed ID: 16755290
[TBL] [Abstract][Full Text] [Related]
6. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
Brusselaers N; Lagergren J
BMJ Open; 2018 Jul; 8(7):e021869. PubMed ID: 29982219
[TBL] [Abstract][Full Text] [Related]
7. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
García Rodríguez LA; Lagergren J; Lindblad M
Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients.
Hvid-Jensen F; Pedersen L; Funch-Jensen P; Drewes AM
Aliment Pharmacol Ther; 2014 May; 39(9):984-91. PubMed ID: 24617286
[TBL] [Abstract][Full Text] [Related]
9. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
10. Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
Xie SH; Santoni G; Lagergren J
Br J Cancer; 2022 Jan; 126(1):129-133. PubMed ID: 34671128
[TBL] [Abstract][Full Text] [Related]
11. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
Kamal H; Sadr-Azodi O; Engstrand L; Brusselaers N
Hepatology; 2021 Oct; 74(4):2021-2031. PubMed ID: 34018229
[TBL] [Abstract][Full Text] [Related]
12. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
Lindner K; Borchardt C; Schöpp M; Bürgers A; Stock C; Hussey DJ; Haier J; Hummel R
J Exp Clin Cancer Res; 2014 Sep; 33(1):73. PubMed ID: 25175076
[TBL] [Abstract][Full Text] [Related]
14. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
15. Occupation and risk of oesophageal adenocarcinoma and squamous-cell carcinoma: The Nordic Occupational Cancer Study.
Jansson C; Oh JK; Martinsen JI; Lagergren J; Plato N; Kjaerheim K; Pukkala E; Sparén P; Tryggvadottir L; Weiderpass E
Int J Cancer; 2015 Aug; 137(3):590-7. PubMed ID: 25557854
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
17. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation.
Giannini EG; Crespi M; Djahandideh A; Demarzo MG; Moscatelli A; Bodini G; Furnari M; Marabotto E; Plaz Torres MC; Zentilin P; Savarino V
Dig Liver Dis; 2020 Aug; 52(8):862-868. PubMed ID: 32505566
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study.
Kauppila JH; Mattsson F; Brusselaers N; Lagergren J
BMJ Open; 2018 May; 8(5):e021495. PubMed ID: 29748347
[TBL] [Abstract][Full Text] [Related]
19. Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Pandeya N; Webb PM; Sadeghi S; Green AC; Whiteman DC;
Gut; 2010 Jan; 59(1):31-8. PubMed ID: 19875392
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
